- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02470702
Multiple Oritavancin Doses on Safety, Tolerability, and Pharmacokinetics in Healthy Subjects
A Double-Blind Randomized Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Multiple 1200 mg Dose Intravenous Oritavancin Infusions in Healthy Subjects
Study Overview
Detailed Description
Oritavancin has been approved in the United States for the treatment of adult patients with acute bacterial skin and skin structure infections (ABSSSIs) caused or suspected to be caused by susceptible isolates of designated Gram-positive microorganisms. The purpose of this study is to determine the (a) safety and tolerability and (b) pharmacokinetic profile of multiple doses of Oritavancin given over a 7-8 week period.
Cohort 1 will consist of 14 subjects, randomized to receive a total of four doses of either oritavancin or placebo, given once every two weeks in a double-blind fashion.
After completion of cohort 1, a Data Safety Monitoring Board will review the blinded safety data and pharmacokinetics (PK) for cohort 1 and determine whether to continue with cohort 2, modify cohort 2 or end the study. The cohorts for this study are sequential.
Cohort 2 will consist of 14 subjects, randomized to receive a total of eight doses of either oritavancin or placebo (4 subjects) given once every week in a double-blind fashion.
Study Type
Enrollment (Actual)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
Wisconsin
-
West Bend, Wisconsin, United States, 53095
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Subject is able to provide written informed consent before initiation of any study-related procedures.
- Healthy male or female between the ages of 18 and 55 years, inclusive.
- Body mass index (BMI) < 45 kg/m^2.
- Subject is in good health based on medical history and physical examination findings and has no clinically meaningful safety laboratory abnormalities (CBC, blood chemistry, and urinalysis) or 12 lead ECG results, as assessed by the PI.
- Vital signs (BP, pulse and temperature) measured at screening/baseline must be within the following ranges: SBP ≥90 to ≤150 mm Hg, DBP ≥45 to ≤90 mm Hg; Heart Rate ≥ 40 to ≤90 bpm (taken after resting in a supine position for at least 5 minutes).
- Willing to avoid all medications (other than the study drug and acetaminophen/paracetamol for minor aches/pains) during the study. This includes prescription and non-prescription medications, vitamins, herbal supplements, and nutraceuticals.
- Subject is a non-smoker and is willing to abstain from alcohol/illegal drug use for the duration of the study.
- If the female subject is surgically sterile, postmenopausal, or, if of childbearing potential, agrees to use at least 2 highly effective methods of birth control (e.g. prescription oral contraceptives, contraceptive injections, contraceptive patch, intrauterine device, barrier methods, abstinence) or male partner sterilization alone for the duration of the study until 60 days after study drug administration.
Exclusion Criteria:
- Has any condition, including findings in the medical history or in pre-study assessments that constitutes a risk or a contraindication for the participation in the study or completing the study.
- Female subjects of childbearing potential that have a positive test result for human chorionic gonadotropin (hCG) at screening.
- Female subjects who are nursing.
- Positive urine test for alcohol and/or for drugs of abuse at screening.
- Has a history or presence of alcohol/drug abuse within 2 years. Alcohol abuse is defined as regularly consuming >3 units/day (21 units per week for men), >2 units/day (14 units/week) for women. 1 unit of alcohol is defined as a can of 4% beer (330 mL), approximately 190 mL of 6-7% beer (malt liquor), a glass of 40% spirits (30 mL), or a glass of wine (100 mL).
- History of hypersensitivity to drugs with a similar chemical structure (i.e. glycopeptide antibiotics) to oritavancin or any of its excipients.
- Blood or plasma donation within the past 2 months.
- Subjects who participated in other clinical research studies involving the evaluation of other investigational drugs or devices within 30 days or 5 half-lives, whichever is longer, prior to screening and/or unwilling to allow at least two months before participation in another drug trial following the current trial.
- Treatment with any prescription or OTC drugs, within 2 weeks or 5 half-lives, whichever is longer, or herbal nutritional supplements within 2 weeks of screening, with the exception of acetaminophen/paracetamol for minor aches/pains. Subjects will not be allowed to receive medications for the duration of the study (except the above-mentioned acetaminophen/paracetamol). Birth control or other hormone replacement is also permitted as long as it has been taken at a stable dose for at least three months before the screening visit and remains stable for the duration of the study.
- Males who are unwilling to practice abstinence or use an acceptable method of birth control during the entire study period (i.e. condom with spermicide).
- Subjects that have any surgical or medical condition that could interfere with the administration of the study drug.
- Subjects that have known active hepatitis B or C, or human immunodeficiency virus (HIV) infection or has known immune deficiency disease at screening.
- Subjects that have any condition that would confound or interfere with the assessment of safety.
- Subjects that have poor IV access as determined by the investigator. Subjects excluded for any of the previous criteria may only be rescreened for participation after discussion with sponsor and principal investigator.
- Prior exposure to Oritavancin alone or in combination with another product.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Other
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Oritavancin
Subjects randomized to oritavancin will receive four doses (Cohort 1) or eight doses (Cohort 2) of 1200 mg oritavancin, infused intravenously over 3 hours
|
|
Placebo Comparator: Placebo
Subjects randomized to placebo will receive four doses (Cohort 1) or eight doses (Cohort 2) of 1000 mL D5W, infused intravenously over 3 hours
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Safety & Tolerability: AEs/SAEs
Time Frame: From consent until day 110 safety follow up call
|
a composite measure of the number and types of AEs/SAEs encountered and relationship to time of dosing
|
From consent until day 110 safety follow up call
|
Safety & Tolerability: clinical safety laboratory results
Time Frame: From consent until day 110 safety follow up call
|
A composite measure of multiple laboratory results assessing the clinical significance of any changes from baseline
|
From consent until day 110 safety follow up call
|
Safety & Tolerability: vital sign measurements
Time Frame: From consent until day 110 safety follow up call
|
A composite of multiple vital sign measurements, assessing the clinical significance of any changes from baseline
|
From consent until day 110 safety follow up call
|
Safety & Tolerability: ECGs
Time Frame: From consent until day 110 safety follow up call
|
A composite of multiple ECG measurements, assessing the clinical significance of any changes from baseline
|
From consent until day 110 safety follow up call
|
Safety & Tolerability: physical examination findings
Time Frame: From consent until day 110 safety follow up call
|
A composite of multiple physical examination findings, assessing the clinical significance of any changes from baseline
|
From consent until day 110 safety follow up call
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Pharmacokinetics: AUC0-last
Time Frame: From pre-dose until 720 hours past last dose
|
AUC from time zero to the time of the last measurable concentration
|
From pre-dose until 720 hours past last dose
|
Pharmacokinetics: AUC0-72
Time Frame: From pre-dose until 72 hours past last dose
|
AUC from time zero to 72 hours post dose
|
From pre-dose until 72 hours past last dose
|
Pharmacokinetics: AUC0-∞
Time Frame: From pre-dose until 720 hours past last dose
|
AUC from time zero to infinity
|
From pre-dose until 720 hours past last dose
|
Pharmacokinetics: Cmax
Time Frame: From pre-dose until 720 hours past last dose
|
maximum measured plasma concentration
|
From pre-dose until 720 hours past last dose
|
Pharmacokinetics: Cmin
Time Frame: From pre-dose until 720 hours past last dose
|
minimum plasma concentration
|
From pre-dose until 720 hours past last dose
|
Pharmacokinetics: Tmax
Time Frame: From pre-dose until 720 hours past last dose
|
time to Cmax
|
From pre-dose until 720 hours past last dose
|
Pharmacokinetics: t1/2
Time Frame: From pre-dose until 720 hours past last dose
|
elimination half- life
|
From pre-dose until 720 hours past last dose
|
Pharmacokinetics: CL
Time Frame: From pre-dose until 720 hours past last dose
|
total body clearance
|
From pre-dose until 720 hours past last dose
|
Pharmacokinetics: VSS
Time Frame: From pre-dose until 720 hours past last dose
|
Volume of distribution
|
From pre-dose until 720 hours past last dose
|
Collaborators and Investigators
Sponsor
Investigators
- Study Director: Medical Information, Melinta Therapeutics, Inc.
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimated)
Study Record Updates
Last Update Posted (Estimated)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- MDCO-ORI-15-02
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Healthy
-
Prevent Age Resort "Pervaya Liniya"RecruitingHealthy Aging | Healthy Diet | Healthy LifestyleRussian Federation
-
Maastricht University Medical CenterCompletedHealthy Volunteers | Healthy Subjects | Healthy AdultsNetherlands
-
Yale UniversityNot yet recruitingHealth-related Benefits of Introducing Table Olives Into the Diet of Young Adults: Olives For HealthHealthy Diet | Healthy Lifestyle | Healthy Nutrition | CholesterolUnited States
-
University of PennsylvaniaActive, not recruitingHealthy | Healthy AgingUnited States
-
Chalmers University of TechnologyGöteborg UniversityCompletedHealthy | Nutrition, HealthySweden
-
Hasselt UniversityRecruitingHealthy | Healthy AgingBelgium
-
Galera Therapeutics, Inc.Syneos HealthCompleted
-
Galera Therapeutics, Inc.Syneos HealthCompletedHealthy | Healthy VolunteersAustralia
-
University of ManitobaNot yet recruitingHealthy | Healthy Diet
Clinical Trials on Oritavancin
-
Targanta Therapeutics CorporationCompletedWounds and Injuries | Streptococcal Infections | Abscess | Cellulitis | Staphylococcal Skin InfectionsUnited States, Australia, India, Italy, Romania, Ukraine
-
Melinta Therapeutics, Inc.Completed
-
Melinta Therapeutics, Inc.Completed
-
University of PennsylvaniaWithdrawnStaphylococcus Aureus Bacteremia | Staphylococcus Aureus EndocarditisUnited States
-
Melinta Therapeutics, Inc.CompletedAcute Bacterial Skin and Skin Structure InfectionUnited States
-
Melinta Therapeutics, Inc.Completed
-
The Medicines CompanyCompleted
-
Melinta Therapeutics, LLCRecruitingGram Positive Bacterial InfectionsUnited States
-
Melinta Therapeutics, Inc.Christchurch Clinical Studies Trust LtdCompletedHealthy VolunteersNew Zealand
-
Melinta Therapeutics, LLCRecruitingAcute Bacterial Skin and Skin Structure InfectionUnited States, Spain, Greece, Portugal, Bulgaria, Latvia, Romania, Lithuania, Poland